Avacta Group Plc

OTCPK:AVCT.F Stock Report

Market Cap: US$229.6m

Avacta Group Valuation

Is AVCT.F undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of AVCT.F when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate AVCT.F's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate AVCT.F's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for AVCT.F?

Key metric: As AVCT.F is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for AVCT.F. This is calculated by dividing AVCT.F's market cap by their current revenue.
What is AVCT.F's PS Ratio?
PS Ratio8.1x
SalesUK£22.62m
Market CapUK£182.95m

Price to Sales Ratio vs Peers

How does AVCT.F's PS Ratio compare to its peers?

The above table shows the PS ratio for AVCT.F vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average7.3x
MRSN Mersana Therapeutics
7.7x33.4%US$247.1m
VYGR Voyager Therapeutics
1.9x-11.7%US$314.1m
PRQR ProQR Therapeutics
18.4x31.6%US$365.3m
STRO Sutro Biopharma
1.3x27.4%US$215.2m
AVCT.F Avacta Group
8.1x0.4%US$182.9m

Price-To-Sales vs Peers: AVCT.F is expensive based on its Price-To-Sales Ratio (8.1x) compared to the peer average (7.3x).

Price to Sales Ratio vs Industry

How does AVCT.F's PS Ratio compare vs other companies in the US Biotechs Industry?

126 CompaniesPrice / SalesEstimated GrowthMarket Cap
BIIB Biogen
2.4x1.3%US$23.13b
MRNA Moderna
3.2x6.7%US$16.80b
INCY Incyte
3.5x9.0%US$14.16b
ALKS Alkermes
3.1x-0.7%US$4.75b
AVCT.F 8.1xIndustry Avg. 9.4xNo. of Companies126PS01632486480+
126 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: AVCT.F is good value based on its Price-To-Sales Ratio (8.1x) compared to the US Biotechs industry average (9.4x).

Price to Sales Ratio vs Fair Ratio

What is AVCT.F's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

AVCT.F PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio8.1x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate AVCT.F's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst AVCT.F forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Currentn/a
US$1.13
0%
33.1%US$1.50US$0.50n/a4
Nov ’25n/a
US$1.46
0%
55.6%US$2.51US$0.53n/a3
Oct ’25US$0.70
US$1.46
+110.0%
55.6%US$2.51US$0.53n/a3
Sep ’25n/a
US$1.43
0%
55.6%US$2.46US$0.52n/a3
Aug ’25n/a
US$1.39
0%
55.2%US$2.38US$0.51n/a3
Jul ’25n/a
US$1.39
0%
55.2%US$2.38US$0.51n/a3
Jun ’25US$0.51
US$1.03
+102.6%
36.4%US$1.32US$0.50n/a3
May ’25US$0.59
US$1.16
+96.3%
17.2%US$1.32US$0.88n/a3
Apr ’25US$0.62
US$1.17
+87.0%
17.2%US$1.33US$0.88n/a3
Mar ’25US$0.67
US$1.61
+141.8%
34.1%US$2.21US$0.88n/a3
Feb ’25n/a
US$1.82
0%
32.3%US$2.41US$0.89n/a4
Jan ’25n/a
US$1.76
0%
31.6%US$2.43US$0.89n/a4
Dec ’24US$1.67
US$1.94
+16.4%
36.3%US$2.78US$0.85n/a4
Nov ’24n/a
US$2.31
0%
16.1%US$2.78US$1.88n/a3
Oct ’24US$1.90
US$2.31
+21.3%
16.1%US$2.78US$1.88US$0.703
Sep ’24n/a
US$2.59
0%
10.4%US$2.86US$2.32n/a2
Aug ’24n/a
US$2.59
0%
10.4%US$2.86US$2.32n/a2
Jul ’24n/a
US$2.59
0%
10.4%US$2.86US$2.32n/a2
Jun ’24US$1.50
US$2.59
+72.5%
10.4%US$2.86US$2.32US$0.512
Nov ’23n/a
US$2.45
0%
17.1%US$2.86US$2.03n/a2

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

Teva Pharmaceutical Industries

US$18.9b

Develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally.

TEVA

US$16.59

7D

-1.3%

1Y

69.3%

Collegium Pharmaceutical

US$993.0m

A specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management.

COLL

US$31.19

7D

4.8%

1Y

22.3%

IQVIA Holdings

US$37.0b

Engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific.

IQV

US$201.23

7D

5.2%

1Y

-4.6%